Illustration: Tiffany Herring/Axios
Johnson & Johnson agreed to buy Halda Therapeutics, a precision cancer treatment startup, for $3.05 billion in cash, the companies said Monday.
The big picture: The deal helps J&J expand its solid tumor and prostate cancer treatment portfolio.
